Go offline with the Player FM app!
Unpacking the Potential of HER3-Targeted Therapy in NSCLC
Manage episode 391779564 series 3256997
This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including:
- Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trial
- The EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamab
- The HER2xHER3 bispecific antibody zenocutuzumab
- The HER3-targeted antibody–drug conjugate SHR-A2009
Presenters in this series include:
Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts
Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Supported by an educational grant from Daiichi Sankyo, Inc.
Link to full program, including a downloadable highlights slideset:
https://bit.ly/48ecElW
192 episodes
Manage episode 391779564 series 3256997
This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including:
- Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trial
- The EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamab
- The HER2xHER3 bispecific antibody zenocutuzumab
- The HER3-targeted antibody–drug conjugate SHR-A2009
Presenters in this series include:
Rebecca S. Heist, MD, MPH
Associate Professor of Medicine
Harvard Medical School
Medical Oncology
Massachusetts General Hospital
Boston, Massachusetts
Helena Yu, MD
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Supported by an educational grant from Daiichi Sankyo, Inc.
Link to full program, including a downloadable highlights slideset:
https://bit.ly/48ecElW
192 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.